About this trial
Patient Profile
Primary Myelofibrosis, Post-PV or Post-ET Myelofibrosis
Where’s this trial being run?
Cork University Hospital, St James’s Hospital, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | FEDR-MF-002/FREEDOM-2 |
|---|---|
| Number: | CTRIAL-IE 19-40 |
| Full Title: | A phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS-intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib |
| Principal Investigator: | Eibhlin Conneally |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Celgene |
| Recruitment Started: |
Global: Ireland: |
| Global Recruitment Target: | 192 |
|---|---|
| Ireland Recruitment Target: | 6 |